Centiva Capital, LP Fate Therapeutics Inc Transaction History

Centiva Capital, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$2.02 - $5.04 $406 - $1,013	-201 Reduced 0.83%	23,885 $50,000
Q2 2023 Aug 14, 2023	BUY	$4.76 - $6.59 $114,649 - $158,726	24,086 New	24,086 $114,000
Q3 2021 Nov 15, 2021	SELL	$59.27 - $95.73 $167,200 - $270,054	-2,821 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$67.25 - $92.52 $189,712 - $260,998	2,821 New	2,821 $245,000
Q3 2020 Nov 16, 2020	SELL	$30.41 - $40.5 $341,656 - $455,017	-11,235 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$20.21 - $35.23 $227,059 - $395,809	11,235 New	11,235 $385,000

179

113M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $127M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Centiva Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Centiva Capital, LP with notifications on news.